Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide vs Octreotide in Acromegaly
NCT00088582Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2004
- Primary completion
- Oct 2005
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pasireotide LAR in acromegaly (2 arms), sponsored by Novartis. Primary endpoints: Growth Hormone Concentration at 6 months and Insulin-like Growth Factor 1 Concentration at 6 months. Started Mar 2004; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00088582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088582.